Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Giant cell tumours
- Focus Adverse reactions
- Sponsors Amgen
- 16 Jul 2018 Planned End Date changed from 22 Jul 2023 to 19 Jul 2023.
- 16 Jul 2018 Planned primary completion date changed from 22 Jul 2023 to 19 Jul 2023.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.